Delete lines 4 through 12 of the printed bill and insert:

"SECTION 1. Section 2 of this 2023 Act is added to and made a part of ORS chapter 689.

SECTION 2. (1) A requirement that a health care provider who is authorized to pre-
scribe drugs in this state label a drug dispensed by the health care provider with the infor-
mation described in subsection (2) of this section does not apply to a drug approved by the
United States Food and Drug Administration for the reversal of an opioid overdose if the
drug is:

(a) In the form of a nasal spray; and

(b) Personally dispensed by a health care provider described in this subsection at the
location of practice of the health care provider.

(2) The information described in subsection (1) of this section includes:

(a) The name of the patient;

(b) The name and address of the dispensing health care provider;

(c) The date of dispensing;

(d) (A) The name of the drug or, if the dispensed drug does not have a brand name, the
generic name of the drug along with the name of the drug distributor or manufacturer;

(B) The drug's quantity per unit, unless the drug is a compound; and

(C) The directions for the drug's use stated in the prescription;

(e) Cautionary statements, if any, as required by law; and

(f) When applicable and as determined by the State Board of Pharmacy, an expiration
date after which the patient should not use the drug.

SECTION 3. Section 2 of this 2023 Act applies to dispensations made on or after the ef-
fective date of this 2023 Act."